Serum CYR61 Is Associated with Disease Activity in Graves’ Orbitopathy

Young Jun Woo, Yuri Seo, Jin Joo Kim, Ji Won Kim, Yil Park, Jinsook Yoon

Research output: Contribution to journalArticle

Abstract

Purpose: To investigate the clinical implications of cysteine-rich angiogenic inducer 61 (CYR61) in Graves’ orbitopathy (GO). Methods: Sera from 52 GO patients, 23 Graves’ disease (GD) patients, and 20 healthy controls, and orbital fat tissue samples from 12 of 52 GO patients and 8 control subjects were included for analysis. Concentrations of CYR61 were measured from sera with an enzyme-linked immunosorbent assay, and CYR61 mRNA expression levels were evaluated from orbital fat tissue with polymerase chain reaction. Results: Serum CYR61 levels were higher in GO patients than in controls (p = 0.001). Patients with active GO showed higher CYR61 levels than those with inactive GO (p < 0.001) or GD (p = 0.004). Expression of CYR61 mRNA was 7.4-fold higher in patients with GO than in healthy controls (p < 0.001). Conclusions: CYR61 could be an adjuvant biomarker associated with the inflammatory activity of GO.

Original languageEnglish
Pages (from-to)1094-1100
Number of pages7
JournalOcular Immunology and Inflammation
Volume26
Issue number7
DOIs
Publication statusPublished - 2018 Oct 3

Fingerprint

Cysteine
Serum
Graves Disease
Fats
Messenger RNA
Biomarkers
Enzyme-Linked Immunosorbent Assay
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Ophthalmology

Cite this

Woo, Young Jun ; Seo, Yuri ; Kim, Jin Joo ; Kim, Ji Won ; Park, Yil ; Yoon, Jinsook. / Serum CYR61 Is Associated with Disease Activity in Graves’ Orbitopathy. In: Ocular Immunology and Inflammation. 2018 ; Vol. 26, No. 7. pp. 1094-1100.
@article{5c7d09c199d74f598e29c3bf10328c97,
title = "Serum CYR61 Is Associated with Disease Activity in Graves’ Orbitopathy",
abstract = "Purpose: To investigate the clinical implications of cysteine-rich angiogenic inducer 61 (CYR61) in Graves’ orbitopathy (GO). Methods: Sera from 52 GO patients, 23 Graves’ disease (GD) patients, and 20 healthy controls, and orbital fat tissue samples from 12 of 52 GO patients and 8 control subjects were included for analysis. Concentrations of CYR61 were measured from sera with an enzyme-linked immunosorbent assay, and CYR61 mRNA expression levels were evaluated from orbital fat tissue with polymerase chain reaction. Results: Serum CYR61 levels were higher in GO patients than in controls (p = 0.001). Patients with active GO showed higher CYR61 levels than those with inactive GO (p < 0.001) or GD (p = 0.004). Expression of CYR61 mRNA was 7.4-fold higher in patients with GO than in healthy controls (p < 0.001). Conclusions: CYR61 could be an adjuvant biomarker associated with the inflammatory activity of GO.",
author = "Woo, {Young Jun} and Yuri Seo and Kim, {Jin Joo} and Kim, {Ji Won} and Yil Park and Jinsook Yoon",
year = "2018",
month = "10",
day = "3",
doi = "10.1080/09273948.2017.1319960",
language = "English",
volume = "26",
pages = "1094--1100",
journal = "Ocular Immunology and Inflammation",
issn = "0927-3948",
publisher = "Informa Healthcare",
number = "7",

}

Serum CYR61 Is Associated with Disease Activity in Graves’ Orbitopathy. / Woo, Young Jun; Seo, Yuri; Kim, Jin Joo; Kim, Ji Won; Park, Yil; Yoon, Jinsook.

In: Ocular Immunology and Inflammation, Vol. 26, No. 7, 03.10.2018, p. 1094-1100.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum CYR61 Is Associated with Disease Activity in Graves’ Orbitopathy

AU - Woo, Young Jun

AU - Seo, Yuri

AU - Kim, Jin Joo

AU - Kim, Ji Won

AU - Park, Yil

AU - Yoon, Jinsook

PY - 2018/10/3

Y1 - 2018/10/3

N2 - Purpose: To investigate the clinical implications of cysteine-rich angiogenic inducer 61 (CYR61) in Graves’ orbitopathy (GO). Methods: Sera from 52 GO patients, 23 Graves’ disease (GD) patients, and 20 healthy controls, and orbital fat tissue samples from 12 of 52 GO patients and 8 control subjects were included for analysis. Concentrations of CYR61 were measured from sera with an enzyme-linked immunosorbent assay, and CYR61 mRNA expression levels were evaluated from orbital fat tissue with polymerase chain reaction. Results: Serum CYR61 levels were higher in GO patients than in controls (p = 0.001). Patients with active GO showed higher CYR61 levels than those with inactive GO (p < 0.001) or GD (p = 0.004). Expression of CYR61 mRNA was 7.4-fold higher in patients with GO than in healthy controls (p < 0.001). Conclusions: CYR61 could be an adjuvant biomarker associated with the inflammatory activity of GO.

AB - Purpose: To investigate the clinical implications of cysteine-rich angiogenic inducer 61 (CYR61) in Graves’ orbitopathy (GO). Methods: Sera from 52 GO patients, 23 Graves’ disease (GD) patients, and 20 healthy controls, and orbital fat tissue samples from 12 of 52 GO patients and 8 control subjects were included for analysis. Concentrations of CYR61 were measured from sera with an enzyme-linked immunosorbent assay, and CYR61 mRNA expression levels were evaluated from orbital fat tissue with polymerase chain reaction. Results: Serum CYR61 levels were higher in GO patients than in controls (p = 0.001). Patients with active GO showed higher CYR61 levels than those with inactive GO (p < 0.001) or GD (p = 0.004). Expression of CYR61 mRNA was 7.4-fold higher in patients with GO than in healthy controls (p < 0.001). Conclusions: CYR61 could be an adjuvant biomarker associated with the inflammatory activity of GO.

UR - http://www.scopus.com/inward/record.url?scp=85019701889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019701889&partnerID=8YFLogxK

U2 - 10.1080/09273948.2017.1319960

DO - 10.1080/09273948.2017.1319960

M3 - Article

VL - 26

SP - 1094

EP - 1100

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

SN - 0927-3948

IS - 7

ER -